ClinicalTrials.gg
RecruitingNCT07185958DARTUpdated Oct 29, 2026

Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy

An observational study in Brain Metastases, Bone Metastases and Head and Neck Cancer, sponsored by Aalborg University Hospital. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Aalborg University Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Brain Neoplasms with a site in Denmark — 10 open to participants now, 14 under way, 3 of them phase 3. Brain Neoplasms · Denmark.

Planned enrollment
8th of 11
80 · median 150
Started
2025
with 1 other
Observational
11 of 38
3 open now
Primary completion
2028-03
later than 8 of 13 live
Registered
35th of 38
by date
Lead sponsor
1 of 38
Aalborg University Hospital

Among the 38 studies in Brain Neoplasms with a site in Denmark, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, reaches primary completion later than 8 of the 13 other live ones, and was the 35th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

10 of the 38 studies in Brain Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Brain Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and/or contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H\&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H\&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)/CT scan currently used in clinical practice.

Read the detailed description

A detailed description of the study is provided in the uploaded document 'Study Protocol with Statistical Analysis Plan'.

03

Conditions studied

  • Brain Metastases
  • Bone Metastases
  • Head and Neck Cancer
  • Lung Cancer

Keywords

  • tumor delineation
  • organs at risk delineation
  • dual-energy CT
  • DECT
  • radiotherapy
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients referred for radiotherapy at Aalborg University Hospital, Denmark. For the 'DART Bone (SBRT)' cohort, patients are also referred for radiotherapy at Odense University Hospital and Copenhagen University Hospital, Herlev and Gentofte, Denmark

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. performance status (PS) 0-2
  3. Assessed to be able to complete the protocol scanning regime
  4. Referred for RT
  5. Signed
  6. For patients with (cohort A): 1-5 brain metastases referred for ei-ther whole brain or stereotactic RT
  7. For patients with bone (cohort B): Metastases in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum), without medullary involve-ment, referred for either palliative or stereotactic RT
  8. For head and neck cancer patients (cohort C): A PET/CT scan must have been per-formed during the diagnostic evaluation for cancer
  9. For lung cancer patients (cohort D): Only patients referred for palliative RT with a maximum of 10 fractions

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy
  2. Previous RT in the same anatomical area now referred for RT
  3. Previous surgery in the same anatomical area now referred for RT
  4. Participation in conflicting protocols
  5. If relevant for the protocol scanning regime: Allergic to contrast agent
  6. If relevant for the protocol scanning regime: to iodine-based contrast agent for CT (as determined by the physician)
  7. If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician)
  8. If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.)
  9. Incapable of understanding the patient information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • DART Brain (whole)

    Patients with 1-5 brain metastases referred for whole brain radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent + extra MRI scan with Gadolinium-based contrast agent.

    Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent · Diagnostic Test: Magnetic Resonance Imaging (MRI) · Drug: Gadolinium-based contrast agent

  • DART Brain (SRS)

    Patients with 1-5 brain metastases referred for stereotactic radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent.

    Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent

  • DART Bone (pall)

    Patients with bone metastases without medullary involvement in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum) referred for palliative radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent + extra MRI scan without contrast agent.

    Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent · Diagnostic Test: Magnetic Resonance Imaging (MRI)

  • DART Bone (SBRT)

    Patients with bone metastases without medullary involvement in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum) referred for palliative radiotherapy. Intervention: Extra DECT scan with iodine-based contrast agent.

    Diagnostic Test: Dual-energy CT (DECT) · Drug: Iodine-based contrast agent

  • DART H&N

    Patients with head and neck cancer referred for radiotherapy. Patients must have undergone a PET/CT scan during the diagnostic evaluation for cancer. Intervention: Extra DECT scan without contrast agent.

    Diagnostic Test: Dual-energy CT (DECT)

  • DART Lung

    Patients with lung cancer referred for palliative radiotherapy with a maximum of 10 fractions. Interventions: Extra DECT scan in breath-hold without contrast agent.

    Diagnostic Test: Dual-energy CT (DECT)

Interventions

  • Diagnostic testDual-energy CT (DECT)

    Additional DECT scan performed for tumor and OAR delineation.

  • DrugIodine-based contrast agent

    Administered intravenously with DECT for enhanced imaging.

  • Diagnostic testMagnetic Resonance Imaging (MRI)

    Additional MRI scan performed for tumor and OAR delineation.

  • DrugGadolinium-based contrast agent

    Administered intravenously with MRI for enhanced imaging.

06

What researchers measure

Primary outcomes

  1. Inter-observer variability (geometric differences in volume and surface) of manual tumor and OAR delineations on DECT compared with SECT/MRI.

    For patients enrolled in cohorts 'DART Brain', 'DART Bone' and 'DART H\&N', the accuracy of manual delineations of tumors and OARs on DECT scans will be compared to those manually performed on a combination of SECT and MRI scans for each patient. For patients enrolled in 'DART H\&N' the comparison will also be done to the PET/CT scan. A reduction in inter-observer variability in delineations will serve as an indicator of improved contour accuracy for both tumors and OARs. Inter-observer variability for tumor and OAR delineations on DECT and SECT/MRI scans, respectively, will be measured as geometric differences between individual manual delineations and consensus structures for each tumor and OAR. Consensus structures will be generated on both DECT and SECT/MRI scans using the STAPLE function with a 50% agreement threshold. Variations relative to the consensus structures will be reported using various metrics, including volume and surface differences.

    Time frame: Baseline (time of imaging before radiotherapy planning)

Secondary outcomes

  1. Qualitative image-quality assessment of tumors and OARs using a Likert scale (or comparable method) for DECT compared with SECT/MRI.

    The secondary outcome will be measured in all patient cohorts ('DART Brain', 'DART Bone', 'DART H\&N', and 'DART Lung'). Image-quality for tumors and OARs will be evaluated qualitatively by experienced oncologists using a 5-point Likert scale (ranging from 1 to 5, where a score of 1 represents the highest image quality and 5 represents the lowest/worst quality). Evaluations will be made and reported between DECT and SECT/MRI scans (and, for patients enrolled in 'DART H\&N', also PET/CT scans).

    Time frame: Baseline (time of imaging before radiotherapy planning)

07

Study locations

2 of 3 sites recruiting
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
    Recruiting
    • Hella MB Sand, Medical Physicist, MSc · Contacthmbs@rn.dk · +45 97 66 15 84
    • Laurids Ø Poulsen, Clinical Oncologist, MD, PhD · Contactlaop@rn.dk · +45 97 66 67 95
    • Jimmi Søndergaard, Clinical Oncologist, MD, PhD · Sub investigator
    • Martin S Nielsen, Medical Physicist, MSc, PhD · Sub investigator
    • Laurids Ø Poulsen, Clinical Oncologist, MD, PhD · Sub investigator
  • Copenhagen University Hospital Herlev and Gentofte
    Herlev, 2730, Denmark
    Not yet recruiting
    • Jens Edmund, Medical Physicist, MSc, PhD · Contactjens.edmund@regionh.dk · +45 38 68 26 48
    • Gitte Persson, Clinical Oncologist, MD, PhD · Sub investigator
    • Mette Felter, Clinical Oncologist, MD, PhD · Sub investigator
    • Jens Edmund, Medical Physicist, MSc, PhD · Sub investigator
  • Odense University Hospital
    Odense, 5000, Denmark
    Recruiting
    • Tine Schytte, Clinical Oncologist, MD, PhD · Contacttine.schytte@rsyd.dk · +45 40 23 91 93
    • Tine Bjørn, Medical Physicst, MSc, PhD · Sub investigator
    • Rasmus L Christiansen, Medical Physicist, MSc, PhD · Sub investigator
    • Tine Schytte, Clinical Oncologist, MD, PhD · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 29 months is below that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2025, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2025
First posted
Sep 22, 2025
StartActual
Oct 14, 2025was Sep 2025
Primary completionEst.
Mar 21, 2028
CompletionEst.
Mar 21, 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
Show 3 sites
  • Aalborg University Hospital · Aalborg, Denmarkno status→Recruiting
  • Copenhagen University Hospital Herlev and Gentofte · Herlev, Denmarkno status→Not yet recruiting
  • Odense University Hospital · Odense, Denmarkno status→Recruiting
Oct 29, 2026
Start date
Sep 22, 2025→Oct 14, 2025 (actual)
Oct 29, 2026
Eligibility
1 inclusion criterion edited, 4 added
What changed in the criteria
Inclusion criteria
  • AddedAge ≥18 years
  • AddedFor patients with brain metastasis (cohort A): 1-5 brain metastases referred for ei-ther whole brain or stereotactic RT
  • AddedFor patients with bone metastasis (cohort B): Metastases in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum), without medullary involve-ment, referred for either palliative or stereotactic RT
  • EditedFor head and neck cancer patients, a (cohort C): A PET/CT scan must have been performedper-formed during the diagnostic evaluation for cancer
  • AddedFor lung cancer patients (cohort D): Only patients referred for palliative RT with a maximum of 10 fractions
Oct 29, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionQualitative image-quality assessment of tumors and OARs using a Likert scale (or comparable method) for DECT compared with SECT/MRI.: how it is measured was reworded
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
    Show 3 sites
    • Aalborg University Hospital · Aalborg, Denmarkno status→Recruiting
    • Copenhagen University Hospital Herlev and Gentofte · Herlev, Denmarkno status→Not yet recruiting
    • Odense University Hospital · Odense, Denmarkno status→Recruiting
    Start date Sep 22, 2025→Oct 14, 2025 (now actual)
    Eligibility 1 inclusion criterion edited, 4 added
    What changed in the criteria
    Inclusion criteria
    • AddedAge ≥18 years
    • AddedFor patients with brain metastasis (cohort A): 1-5 brain metastases referred for ei-ther whole brain or stereotactic RT
    • AddedFor patients with bone metastasis (cohort B): Metastases in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum), without medullary involve-ment, referred for either palliative or stereotactic RT
    • EditedFor head and neck cancer patients, a (cohort C): A PET/CT scan must have been performedper-formed during the diagnostic evaluation for cancer
    • AddedFor lung cancer patients (cohort D): Only patients referred for palliative RT with a maximum of 10 fractions
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionQualitative image-quality assessment of tumors and OARs using a Likert scale (or comparable method) for DECT compared with SECT/MRI.: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07185958
Collaborators
Copenhagen University Hospital at Herlev, Odense University Hospital
Responsible party
Hella Maria Brøgger Sand (Principal Investigator, Aalborg University Hospital) — Principal investigator
First posted
Sep 22, 2025
Start date
Oct 14, 2025
Primary completion
Mar 21, 2028 (estimated)
Completion
Mar 21, 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Hella MB Sand, Medical Physicist, MSc
Contact
hmbs@rn.dk
+45 97 66 15 84
Laurids Ø Poulsen, Clinical Oncologist, MD, PhD
Contact
laop@rn.dk
+45 97 66 67 95
Hella MB Sand, Medical Physicist, MSc
principal investigator · Department of Medical Physics, Oncology, Aalborg University Hospital, Aalborg, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion